Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Dr Reddy’s Laboratories ( (RDY) ) just unveiled an update.
Dr. Reddy’s Laboratories has announced the incorporation of a new wholly-owned subsidiary, Dr. Reddy’s Finland Oy, under its existing subsidiary, Dr. Reddy’s Laboratories SA, Switzerland. This strategic move aims to enhance the company’s presence in the European market by aligning with its core business of pharmaceuticals and healthcare products. The new entity, based in Finland, is expected to facilitate the marketing, sales, and promotion of medical devices and related products, further strengthening Dr. Reddy’s market position in the region.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories is a prominent player in the pharmaceutical and healthcare industry, primarily involved in the production and marketing of healthcare-related products, including pharmaceuticals, medical devices, and consulting services. The company has a global presence with a focus on expanding its operations internationally.
YTD Price Performance: 11.00%
Average Trading Volume: 1,063,136
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $13.17B
Learn more about RDY stock on TipRanks’ Stock Analysis page.
